Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Nature. 2023 Jan;613(7944):508-518. doi: 10.1038/s41586-022-05473-8. Epub 2023 Jan 18.
Population isolates such as those in Finland benefit genetic research because deleterious alleles are often concentrated on a small number of low-frequency variants (0.1% ≤ minor allele frequency < 5%). These variants survived the founding bottleneck rather than being distributed over a large number of ultrarare variants. Although this effect is well established in Mendelian genetics, its value in common disease genetics is less explored. FinnGen aims to study the genome and national health register data of 500,000 Finnish individuals. Given the relatively high median age of participants (63 years) and the substantial fraction of hospital-based recruitment, FinnGen is enriched for disease end points. Here we analyse data from 224,737 participants from FinnGen and study 15 diseases that have previously been investigated in large genome-wide association studies (GWASs). We also include meta-analyses of biobank data from Estonia and the United Kingdom. We identified 30 new associations, primarily low-frequency variants, enriched in the Finnish population. A GWAS of 1,932 diseases also identified 2,733 genome-wide significant associations (893 phenome-wide significant (PWS), P < 2.6 × 10) at 2,496 (771 PWS) independent loci with 807 (247 PWS) end points. Among these, fine-mapping implicated 148 (73 PWS) coding variants associated with 83 (42 PWS) end points. Moreover, 91 (47 PWS) had an allele frequency of <5% in non-Finnish European individuals, of which 62 (32 PWS) were enriched by more than twofold in Finland. These findings demonstrate the power of bottlenecked populations to find entry points into the biology of common diseases through low-frequency, high impact variants.
人群隔离体,如芬兰的人群,有益于遗传研究,因为有害等位基因通常集中在少数低频变异体上(0.1%≤次要等位基因频率<5%)。这些变异体在奠基者瓶颈期幸存下来,而不是分布在大量超罕见的变异体中。尽管这一效应在孟德尔遗传学中已得到充分证实,但在常见疾病遗传学中的价值尚未得到充分探索。芬兰遗传研究(FinnGen)旨在研究 50 万芬兰个体的基因组和国家健康登记数据。考虑到参与者的中位年龄相对较高(63 岁)以及大量基于医院的招募,芬兰遗传研究富集了疾病终点。在这里,我们分析了来自 FinnGen 的 224737 名参与者的数据,并研究了之前在大型全基因组关联研究(GWAS)中研究过的 15 种疾病。我们还包括爱沙尼亚和英国生物银行数据的荟萃分析。我们鉴定出 30 个新的关联,主要是低频变异体,在芬兰人群中富集。对 1932 种疾病的 GWAS 也在 2496 个独立位点(807 个表型广泛显著(PWS),P<2.6×10)鉴定出 2733 个全基因组显著关联(893 个 PWS),有 807 个终点(247 个 PWS)。其中,精细映射暗示了 148 个与 83 个终点相关的编码变异体(73 个 PWS)。此外,91 个(47 个 PWS)在非芬兰欧洲个体中的等位基因频率<5%,其中 62 个(32 个 PWS)在芬兰中富集超过两倍。这些发现表明,瓶颈人群通过低频、高影响的变异体,发现了进入常见疾病生物学的切入点。